Sanara Medtech Stock Buy Hold or Sell Recommendation
| SMTI Stock | USD 36.19 0.15 0.41% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Sanara Medtech is 'Cautious Hold'. The recommendation algorithm takes into account all of Sanara Medtech's available fundamental, technical, and predictive indicators you will find on this site.
Check out Sanara Medtech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide. In addition, we conduct extensive research on individual companies such as Sanara and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Sanara |
Execute Sanara Medtech Buy or Sell Advice
The Sanara recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sanara Medtech. Macroaxis does not own or have any residual interests in Sanara Medtech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sanara Medtech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Sanara Medtech Trading Alerts and Improvement Suggestions
| Sanara Medtech had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 64.99 M. Net Loss for the year was (4.3 M) with profit before overhead, payroll, taxes, and interest of 39.48 M. | |
| Sanara Medtech currently holds about 12.68 M in cash with (3.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.53. | |
| Sanara Medtech has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th |
Sanara Medtech Returns Distribution Density
The distribution of Sanara Medtech's historical returns is an attempt to chart the uncertainty of Sanara Medtech's future price movements. The chart of the probability distribution of Sanara Medtech daily returns describes the distribution of returns around its average expected value. We use Sanara Medtech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sanara Medtech returns is essential to provide solid investment advice for Sanara Medtech.
| Mean Return | 0.08 | Value At Risk | -4.68 | Potential Upside | 5.81 | Standard Deviation | 3.13 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sanara Medtech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sanara Stock Institutional Investors
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 13 K | Charles Schwab Investment Management Inc | 2024-09-30 | 11.4 K | Salem Investment Counselors Inc | 2024-09-30 | 11.2 K | Stephens Inc | 2024-09-30 | 10.8 K | Bank Of New York Mellon Corp | 2024-09-30 | 10.5 K | Lazard Asset Management Llc | 2024-09-30 | 7.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 7.4 K | State Board Of Admin Of Florida Retir | 2024-09-30 | 7.1 K | Barclays Plc | 2024-09-30 | 5.7 K | Blackrock Inc | 2024-06-30 | 197 K | Vanguard Group Inc | 2024-09-30 | 173 K |
Sanara Medtech Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 6.4M | (6.2M) | 18.2M | (9.7M) | (3.8M) | (3.6M) | |
| Free Cash Flow | (3.9M) | (5.7M) | (5.6M) | (6.3M) | (3.5M) | (3.3M) | |
| Depreciation | 120.0K | 291.4K | 597.0K | 2.4M | 3.7M | 3.9M | |
| Other Non Cash Items | 187.9K | 447.2K | 426.8K | 2.8M | (2.8M) | (2.6M) | |
| Capital Expenditures | 1.7M | 1.6M | 750.5K | 747.0K | 265.2K | 272.2K | |
| Net Income | (2.8M) | (4.4M) | (8.0M) | (8.1M) | (4.3M) | (4.5M) | |
| End Period Cash Flow | 6.6M | 455.4K | 18.7M | 9.0M | 5.1M | 5.4M | |
| Change To Inventory | (281.2K) | (719.8K) | (1.2M) | (517.3K) | (1.5M) | (1.5M) | |
| Dividends Paid | 10.0M | 583K | 442.5K | 220K | 253K | 240.4K | |
| Change To Netincome | 385.6K | 1.3M | 3.7M | (636.0K) | (731.4K) | (694.8K) |
Sanara Medtech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sanara Medtech or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sanara Medtech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sanara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 1.72 | |
σ | Overall volatility | 3.14 | |
Ir | Information ratio | -0.02 |
Sanara Medtech Volatility Alert
Sanara Medtech currently demonstrates below-average downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of -0.13. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sanara Medtech's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sanara Medtech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sanara Medtech Fundamentals Vs Peers
Comparing Sanara Medtech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sanara Medtech's direct or indirect competition across all of the common fundamentals between Sanara Medtech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sanara Medtech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sanara Medtech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sanara Medtech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sanara Medtech to competition |
| Fundamentals | Sanara Medtech | Peer Average |
| Return On Equity | -0.2 | -0.31 |
| Return On Asset | -0.0508 | -0.14 |
| Profit Margin | (0.11) % | (1.27) % |
| Operating Margin | (0.06) % | (5.51) % |
| Current Valuation | 333.3 M | 16.62 B |
| Shares Outstanding | 8.74 M | 571.82 M |
| Shares Owned By Insiders | 66.56 % | 10.09 % |
| Shares Owned By Institutions | 9.42 % | 39.21 % |
| Number Of Shares Shorted | 207.32 K | 4.71 M |
| Price To Book | 7.98 X | 9.51 X |
| Price To Sales | 4.05 X | 11.42 X |
| Revenue | 64.99 M | 9.43 B |
| Gross Profit | 39.48 M | 27.38 B |
| EBITDA | (289.1 K) | 3.9 B |
| Net Income | (4.3 M) | 570.98 M |
| Cash And Equivalents | 12.68 M | 2.7 B |
| Cash Per Share | 1.53 X | 5.01 X |
| Total Debt | 11.79 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 2.86 X | 2.16 X |
| Book Value Per Share | 4.55 X | 1.93 K |
| Cash Flow From Operations | (3.25 M) | 971.22 M |
| Short Ratio | 7.42 X | 4.00 X |
| Earnings Per Share | (0.99) X | 3.12 X |
| Target Price | 44.0 | |
| Number Of Employees | 107 | 18.84 K |
| Beta | 1.56 | -0.15 |
| Market Capitalization | 316.34 M | 19.03 B |
| Total Asset | 73.87 M | 29.47 B |
| Retained Earnings | (28.04 M) | 9.33 B |
| Working Capital | 5.24 M | 1.48 B |
| Net Asset | 73.87 M |
Note: Acquisition by Morrison Christopher A. of 7135 shares of Sanara Medtech subject to Rule 16b-3 [view details]
Sanara Medtech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sanara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sanara Medtech Buy or Sell Advice
When is the right time to buy or sell Sanara Medtech? Buying financial instruments such as Sanara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sanara Medtech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Crypto And Gold Thematic Idea Now
Crypto And Gold
Assets that cancel away each other volatility by providing diversification into gold investment combined with digital assets. The Crypto And Gold theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Crypto And Gold Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sanara Medtech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 9.241 | Quarterly Revenue Growth 0.352 | Return On Assets (0.05) | Return On Equity (0.20) |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.